704208-25-3

Basic information

• Product Name: 7-(TRIFLUOROMETHYL)CHROMAN-4-AMINE
• Synonyms: 7-(TRIFLUOROMETHYL)CHROMAN-4-AMINE;(7-Trifluoromethylchroman-4-yl)amine;3,4-Dihydro-7-(trifluoromethyl)-2H-1-benzopyran-4-amine
• CAS NO: 704208-25-3
• Molecular Formula: C10H10F3NO
• Molecular Weight: 217.19
• Mol File: 704208-25-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 250℃
• Flash Point: 105℃
• Appearance: /
• Density: 1.289
• Vapor Pressure: 0.023mmHg at 25°C
• Refractive Index: 1.489
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 7-(TRIFLUOROMETHYL)CHROMAN-4-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(TRIFLUOROMETHYL)CHROMAN-4-AMINE(704208-25-3)
• EPA Substance Registry System: 7-(TRIFLUOROMETHYL)CHROMAN-4-AMINE(704208-25-3)

Safety Data

• Hazardous Substances Data: 704208-25-3(Hazardous Substances Data)

Usage

General Description

7-(Trifluoromethyl)chroman-4-amine is a chemical compound with the molecular formula C10H8F3NO. It is a chroman derivative with a trifluoromethyl group attached to the fourth position of the chroman ring. 7-(TRIFLUOROMETHYL)CHROMAN-4-AMINE has potential applications in medicinal chemistry and drug development due to its structural features, which may be relevant for binding to biological targets. It may also be used as a building block in organic synthesis for the preparation of various pharmaceuticals and agrochemicals. However, further research is needed to fully understand the potential uses and properties of 7-(trifluoromethyl)chroman-4-amine.

InChI:InChI=1/C10H10F3NO/c11-10(12,13)6-1-2-7-8(14)3-4-15-9(7)5-6/h1-2,5,8H,3-4,14H2

Upstream product

• 111141-02-7 2,3-dihydro-7-(trifluoromethyl)-4H-1-benzopyran-4-one 
• 890838-99-0 7-trifluoromethyl-chroman-4-one O-methyl-oxime 

Downstream Products

• 1140496-05-4 (S)-7-(trifluoromethyl)chroman-4-amine 

Relevant articles and documents

Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.

Prodrugs of compounds that inhibit TRPV1 receptor

Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladd